Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, +18

Neurology Neuroimmunology & Neuroinflammation

Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome

Christiana Franke, Fabian Boesl, Yasemin Goereci, +12

Brain Behavior and Immunity

Multidomain cognitive impairment in non-hospitalized patients with the post-COVID-19 syndrome: results from a prospective monocentric cohort

Ann‐Katrin Schild, Yasemin Goereci, Daniel Scharfenberg, +14

Journal of Neurology

<scp>Cerebrospinal Fluid</scp> Analysis <scp>Post–COVID</scp>‐19 Is Not Suggestive of Persistent <scp>Central Nervous System</scp> Infection

Finja Schweitzer, Yasemin Goereci, Christiana Franke, +10

Annals of Neurology

Subjective and Objective Cognitive Deficits in Patients with Post-COVID Syndrome

Ann‐Katrin Schild, Daniel Scharfenberg, Lukas Kirchner, +13

Zeitschrift für Neuropsychologie

Psychological Co-morbiditiesNeuropsychologyClinical NeurologyCognitionObjective Cognitive Deficits +17

Cerebrospinal fluid findings in patients with neurological manifestations in post-COVID-19 syndrome

Fabian Boesl, Yasemin Goereci, Ameli Gerhard, +12

Journal of Neurology

Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin‐2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome

Yasemin Goereci, Finja Schweitzer, Anton Wellstein, +9

European Journal of Neurology

Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry

Yasemin Goereci, David Ellenberger, Paulus Rommer, +5

Journal of Neurology

Cognitive decline in post-COVID-19 syndrome does not correspond with persisting neuronal or astrocytic damage

Fabian Boesl, Yasemin Goereci, Finja Schweitzer, +9

Scientific Reports

Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol

Heidrun Golla, Kim Dillen, Martin Hellmich, +24

BMJ Open